-
Feuerstein Says Don't Pile Into AspenBio Pharma (APPY, DSCO)
Monday, July 19, 2010 - 5:12pm | 43Read More...TheStreet.com's Adam Feuerstein tweeted that investors should not pile in on "sad-sack" story AspenBio Pharma (NASDAQ: APPY). He said that APPY = DSCO (Discovery Laboratories)(NASDAQ: DSCO).
-
Tim Sykes And Adam Feuerstein Get Into Spat
Friday, July 2, 2010 - 2:07pm | 283Read More...Penny stock guru Tim Sykes and TheStreet.com's biotech columnist Adam Feuerstein got into a little bit of a spat over Twitter today. Sykes has criticized Jim Cramer for not having a successful track record, and apparently Feuerstein took exception. It appears that Feuerstein tweeted to Sykes about...
-
Adam Feuerstein Continues To Feel Ambivalent About Opexa
Friday, April 9, 2010 - 2:44pm | 227Read More...In an article on TheStreet, Adam Feuerstein said that he continues to have ambivalent feeling about Opexa Therapeutics (NASDAQ: OPXA). The company had reported disappointing phase IIb results of its experimental multiple sclerosis "vaccine" Tovaxin in September 2008. Ever since, OPXA has been...
-
Generex Sues TheStreet.com and Adam Feuerstein (GNBT)
Tuesday, April 6, 2010 - 1:13pm | 292Read More...Generex Biotechnology Corp. (NASDAQ: GNBT) has announced that it has commenced legal proceedings against TheStreet.com (NASDAQ: TSCM) and Adam Feuerstein in the Supreme Court of the State of New York. The company is seeking $250,000 in damages for business defamation, product disparagement, and...
-
Feuerstein Sees PARD as Case of “Sell On News”
Monday, January 25, 2010 - 10:47am | 162Read More...According to Adam Feuerstein, there is a high possibility of Poniard Pharmaceuticals (NASDAQ: PARD) trading down on Monday. PARD had yesterday declared at the American Society of Clinical Oncology (ASCO) meeting that it had met the primary goal of a phase II study for its experimental chemotherapy...
-
Celgene’s (CELG) 2010 Guidance To Set The Trend
Wednesday, January 6, 2010 - 12:22pm | 168Read More...Adam Feuerstein reports on TheStreet.com that Celgene (NASDAQ: CELG) will announce its 2010 guidance at the start of the JPMorgan (NYSE: JPM) Healthcare conference. This is of interest to biotech investors as Celgene’s forecasts often have implications for the entire sector’s outlook. Star drug...
